Our study demonstrated that individual autoantibodies can be detected in a range of 25.5-43.6% of patients with early breast cancer, and the sensitivity was improved to 59.6% when autoantibodies against BMI-1, HSP70, NY-ESO-1 and p53 built as an optimized panel were measured simultaneously. Here, TP53 is linked to breast carcinoma.